of the infections, the comparison between influenza types, the focus on important clinical outcomes, and identification of severity risk factors. The suggestion that high-dose steroids may be beneficial is provocative, but the authors have earlier noted the conflicting data on this point, and randomized trials are clearly needed. Not evaluated in the Choi study was the possible effect of influenza on the subsequent development of noninfectious lung injury or alloreactive syndromes.

Multiple studies have documented substantial morbidity and mortality with seasonal influenza and other community respiratory viruses in HCT recipients. The Choi study emphasizes the importance of early antiviral therapy. Many influenza experts recommend presumptive initiation of therapy for individuals with influenza-like symptoms during times of influenza activity in the community. Consensus guidelines recommend additional measures to protect HCT recipients. Upper respiratory infection (URI) symptoms before start of conditioning should lead one to consider postponement until the URI resolves, if possible, because of the risk for progression to pneumonia. Immunization of patients beyond 6 months after transplant should be performed. Healthcare workers and family members should be immunized to reduce the risk for transmission to the HCT patient. HCT recipients less than 6 months after HCT should receive chemoprophylaxis with neuraminidase inhibitors during community influenza outbreaks. Chemoprophylaxis should be considered for all influenza-exposed HCT recipients during the first 2 years or beyond 2 years if substantially immunocompromised after HCT regardless of vaccination history because of the possibility of suboptimal immunologic response to immunization. Children < 9 years old, less than 6 months after HCT, and receiving their first influenza vaccination, should be given 6 weeks of chemoprophylaxis after the first dose of vaccine. Awareness of drug resistance patterns of circulating influenza strains is advisable and should guide the choice of prophylactic agent.

Seasonal influenza visits every year. What is sobering is how poorly prepared we are for influenza every year. Immunization rates in the general population and among high-risk patients are suboptimal. Failure of many health care workers to get immunized is disappointing. Infection control plans in cancer, leukemia, and HCT inpatient and outpatient facilities are often poorly formulated or not effectively implemented. We clearly can and should do better.4 The Choi study reminds us of the importance of redoubling our efforts to protect our patients not only for pandemics but for a predictable event every winter.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

Comment on Sierra-Filardi et al, page 5092

The yin and yang of Activin A

Silvano Sozzani and Tiziana Musso UNIVERSITY OF BRESCIA; UNIVERSITY OF TURIN

In this issue of Blood, Sierra-Filardi and colleagues shed new light on the still poorly understood proinflammatory role of Activin A in macrophage polarization.1 Activin A is a member of the TGFβ family first identified in late 1980s as an inducer of follicle-stimulating hormone. Similarly to other members of the family, Activin A is highly conserved in evolution and throughout the animal kingdom and regulates a variety of biologic processes including cell proliferation, hematopoiesis, wound healing, and fibrosis. Activin A signals through the activin type I (Alk2, 4, or 7) and type II (ActRII or ActRIIB) receptors and shares with TGFβ the activation of the Smad cascade.2,3 In the past few years the crucial role of TGFβ in the regulation of both innate and adaptive immunity has been thoroughly investigated. In contrast, the role of other members of the TGFβ family in immunity is more elusive and only recently Activin A has attracted the attention of immunologists for the ability to modulate innate and adaptive immune responses.

A role in inflammation is supported by the observation that Activin A is rapidly induced after intravenous injection of LPS with a kinetics that precedes those of primary proinflammatory cytokines, like TNFα, IL-1β, and IL-6. Increased circulating levels of Activin A were reported in certain inflammatory conditions, such as inflammatory bowel disease and rheumatoid arthritis and in humans during bacterial septicemia, hepatitis C infection, and trauma conditions. The role of Activin A in inflammation is further supported by the finding that the administration of follistatin, a natural receptor antagonist, inhibits the onset of the inflammatory cytokine cascade. However, the pure proinflammatory nature of Activin A was challenged in other pathologic situations. In atherosclerosis, Activin A behaves more like an anti-inflammatory mediator being able to inhibit the formation of foam cells. Similarly, in lung hypersensitivity, the systemic administration of Activin A resulted in a protective effect; although in the same experimental model, it acted as a proinflammatory mediator when administered locally.2,3

Many leukocytes, including monocytes, macrophages, dendritic cells, Th2, and B lymphocytes, produce Activin A, with Toll-like receptors being a main pathway of activation.2,3 Consistent with a positive action on immune response, Activin A was shown to
stimulate the production of proinflammatory cytokines, iNOS, and MMP-2 in myeloid cells. Activin A also promoted IgG, and indirectly, IgE production by B cells. In contrast to these pro-inflammatory effects, Activin A was also reported to inhibit cytokine production in human monocytes/macrophages and to attenuate, in an autocrine manner, cytokine production by CD40L-, but not LPS- or Escherichia coli–activated dendritic cells. Finally, Activin A promoted IgG, and indirectly, IgE production by B cells. In contrast to these pro-inflammatory effects, Activin A was also reported to inhibit cytokine production in human monocytes/macrophages and to attenuate, in an autocrine manner, cytokine production by CD40L-, but not LPS- or Escherichia coli–activated dendritic cells. In the mouse, Activin A was also shown to inhibit phagocytosis and NO production in LPS-stimulated macrophages. The dichotomy between the pro- and anti-inflammatory actions of this cytokine is further underscored by the finding that Activin A can control Th1 and Th2 responses through the induction of antigen-specific regulatory T cells. Finally, Activin A was reported to suppress cytokine (IFNγ, IL-6, TNFα, GM-CSF, and IL-1β) and chemokine (MIP-1β, MIP-1α, IL-8, and IP-10) production by activated NK cells, with no effect on their cytotoxic activity.

In this issue of Blood, Sierra-Filardi and colleagues contribute new data to the complex scenario of Activin A regulation of the immune response. Using an in vitro protocol of human blood monocyte polarization to M1 and M2 macrophages, the authors found that M1 cell supernatant is able to inhibit the acquisition of M2 markers by M-CSF–stimulated cells. M1 and M2 macrophages represent the extremes of a broad range of macrophage functional states. M1 macrophages release high levels of IL-12 and IL-23, are characterized by a high production of reactive toxic oxygen species, and mediate resistance against intracellular pathogens. Conversely, M2 macrophages are characterized by the low production of proinflammatory cytokines and play a role in resistance against parasites and in tissue remodeling. As discussed by Sierra-Filardi and colleagues, this report identifies a role for Activin A in the regulation of the transcriptome of M1 versus M2 macrophages and thus in the acquisition of the macrophage proinflammatory phenotype.

This report opens new perspectives but also raises new questions. Macrophages undergo different forms of M1 and M2 polarization according to their in vitro cytokine milieu. For instance, different types of M2 polarization are obtained using IL-4/IL-13, IL-10/glucocorticoids, or LPS/immunocomplexes. At the moment it is unclear whether the action of Activin A observed here in M-CSF–induced M2 macrophages might also be extended to other types of M2 macrophages. A second open issue is the analogy between human and mouse macrophages. Using mouse macrophages, Ogawa et al reported that Activin A increased the expression of arginase, a marker of mouse but not human M2 macrophages, and inhibited IFNγ-induced expression of iNOS, that is again a marker of mouse but not human M1 macrophages. Although both studies highlight a role for Activin A in macrophage polarization, the reason for this apparent discrepancy is unclear. It is possible that the different actions of Activin A should be interpreted in light of the high degree of plasticity that this cytokine shows in relation to the nature of the target cell, the nature of the agonist, and the duration and intensity of the response. In this context it is interesting to note that plasticity and multifaceted responses seem to be common characteristics of other highly evolutionary conserved proteins, such as pentraxins and TGFβ itself, and possibly reflect a strategy to finely tune immune functions with a limited number of effector proteins.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**REFERENCES**

1. Sierra-Filardi E, Puig-Kröger A, Blanco FJ, et al. Activin A skew[s] macrophage polarization by promoting a pro-inflammatory phenotype and inhibiting the acquisition of GM-CSF–stimulated cells. M1 and M2 macrophages represent the extremes of a broad range of macrophage functional states. M1 macrophages release high levels of IL-12 and IL-23, are characterized by a high production of reactive toxic oxygen species, and mediate resistance against intracellular pathogens. Conversely, M2 macrophages are characterized by the low production of proinflammatory cytokines and play a role in resistance against parasites and in tissue remodeling. As discussed by Sierra-Filardi and colleagues, this report identifies a role for Activin A in the regulation of the transcriptome of M1 versus M2 macrophages and thus in the acquisition of the macrophage proinflammatory phenotype.

This report opens new perspectives but also raises new questions. Macrophages undergo different forms of M1 and M2 polarization according to their in vitro cytokine milieu. For instance, different types of M2 polarization are obtained using IL-4/IL-13, IL-10/glucocorticoids, or LPS/immunocomplexes. At the moment it is unclear whether the action of Activin A observed here in M-CSF–induced M2 macrophages might also be extended to other types of M2 macrophages. A second open issue is the analogy between human and mouse macrophages. Using mouse macrophages, Ogawa et al reported that Activin A increased the expression of arginase, a marker of mouse but not human M2 macrophages, and inhibited IFNγ-induced expression of iNOS, that is again a marker of mouse but not human M1 macrophages. Although both studies highlight a role for Activin A in macrophage polarization, the reason for this apparent discrepancy is unclear. It is possible that the different actions of Activin A should be interpreted in light of the high degree of plasticity that this cytokine shows in relation to the nature of the target cell, the nature of the agonist, and the duration and intensity of the response. In this context it is interesting to note that plasticity and multifaceted responses seem to be common characteristics of other highly evolutionary conserved proteins, such as pentraxins and TGFβ itself, and possibly reflect a strategy to finely tune immune functions with a limited number of effector proteins.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**REFERENCES**

1. Sierra-Filardi E, Puig-Kröger A, Blanco FJ, et al. Activin A skew[s] macrophage polarization by promoting a pro-inflammatory phenotype and inhibiting the acquisition of
Thrombin and diabetic nephropathy

Tom van der Poll  CENTER OF INFECTION AND IMMUNITY AMSTERDAM

The coagulation system is regulated by several anticoagulant mechanisms.1 The Protein C system provides important control of coagulation via the capacity of activated protein C (APC) to proteolytically inactivate the coagulation cofactors Va and VIIIa.

Protein C is converted into APC by thrombin bound to thrombomodulin, a receptor present on the vascular endothelium, in a process strongly augmented by the presence of the endothelial protein C receptor (EPCR).

The factor V Leiden (FVL) mutation is a missense mutation in FV gene replacing arginine at position 506 with glutamine, which results in resistance of activated FV to inactivation by APC and causes increased thrombin formation and, thereby, an elevated risk of (mainly venous) thrombotic events.2 The high prevalence of this mutation (4%-6% in Caucasians) despite its prothrombotic effects has prompted speculation that the mutation might be subject to positive selection pressure.3 In the current issue of Blood, Wang et al report that one such evolutionary advantage of the FVL mutation may be protection against diabetic nephropathy (see figure).4

Diabetic nephropathy is a leading cause of end-stage renal failure in the developed world, with albuminuria, a key abnormality, caused by loss and dysfunction of podocytes.5 Wang and colleagues established that the FVL mutation reduces the extent of diabetic nephropathy using an approach that elegantly combines mouse and human studies.6 Relative to normal wild-type mice, heterozygous and homozygous FVL mice displayed reduced albuminuria after 26 weeks of persistent hyperglycemia induced by intraperitoneal administration of streptozotocin. Other manifestations of diabetic nephropathy were also attenuated in FVL mice, including extracellular matrix accumulation, the number of apoptotic cells in glomeruli, and podocyte loss and dysfunction. These findings were corroborated by the observation that type 1 and type 2 diabetes patients heterozygous for the FVL mutation showed reduced albuminuria compared with diabetes patients without FVL who were similar with regard to other risk factors for diabetic nephropathy such as glucose control.

Comment on Wang et al, page 5231

Thrombin and diabetic nephropathy

Tom van der Poll  CENTER OF INFECTION AND IMMUNITY AMSTERDAM

The coagulation system is regulated by several anticoagulant mechanisms.1 The Protein C system provides important control of coagulation via the capacity of activated protein C (APC) to proteolytically inactivate the coagulation cofactors Va and VIIIa.

Protein C is converted into APC by thrombin bound to thrombomodulin, a receptor present on the vascular endothelium, in a process strongly augmented by the presence of the endothelial protein C receptor (EPCR).

The factor V Leiden (FVL) mutation is a missense mutation in FV gene replacing arginine at position 506 with glutamine, which results in resistance of activated FV to inactivation by APC and causes increased thrombin formation and, thereby, an elevated risk of (mainly venous) thrombotic events.2 The high prevalence of this mutation (4%-6% in Caucasians) despite its prothrombotic effects has prompted speculation that the mutation might be subject to positive selection pressure.3 In the current issue of Blood, Wang et al report that one such evolutionary advantage of the FVL mutation may be protection against diabetic nephropathy (see figure).4

Diabetic nephropathy is a leading cause of end-stage renal failure in the developed world, with albuminuria, a key abnormality, caused by loss and dysfunction of podocytes.5 Wang and colleagues established that the FVL mutation reduces the extent of diabetic nephropathy using an approach that elegantly combines mouse and human studies.6 Relative to normal wild-type mice, heterozygous and homozygous FVL mice displayed reduced albuminuria after 26 weeks of persistent hyperglycemia induced by intraperitoneal administration of streptozotocin. Other manifestations of diabetic nephropathy were also attenuated in FVL mice, including extracellular matrix accumulation, the number of apoptotic cells in glomeruli, and podocyte loss and dysfunction. These findings were corroborated by the observation that type 1 and type 2 diabetes patients heterozygous for the FVL mutation showed reduced albuminuria compared with diabetes patients without FVL who were similar with regard to other risk factors for diabetic nephropathy such as glucose control.

Comment on Wang et al, page 5231

Thrombin and diabetic nephropathy

Tom van der Poll  CENTER OF INFECTION AND IMMUNITY AMSTERDAM

The coagulation system is regulated by several anticoagulant mechanisms.1 The Protein C system provides important control of coagulation via the capacity of activated protein C (APC) to proteolytically inactivate the coagulation cofactors Va and VIIIa.

Protein C is converted into APC by thrombin bound to thrombomodulin, a receptor present on the vascular endothelium, in a process strongly augmented by the presence of the endothelial protein C receptor (EPCR).

The factor V Leiden (FVL) mutation is a missense mutation in FV gene replacing arginine at position 506 with glutamine, which results in resistance of activated FV to inactivation by APC and causes increased thrombin formation and, thereby, an elevated risk of (mainly venous) thrombotic events.2 The high prevalence of this mutation (4%-6% in Caucasians) despite its prothrombotic effects has prompted speculation that the mutation might be subject to positive selection pressure.3 In the current issue of Blood, Wang et al report that one such evolutionary advantage of the FVL mutation may be protection against diabetic nephropathy (see figure).4

Diabetic nephropathy is a leading cause of end-stage renal failure in the developed world, with albuminuria, a key abnormality, caused by loss and dysfunction of podocytes.5 Wang and colleagues established that the FVL mutation reduces the extent of diabetic nephropathy using an approach that elegantly combines mouse and human studies.6 Relative to normal wild-type mice, heterozygous and homozygous FVL mice displayed reduced albuminuria after 26 weeks of persistent hyperglycemia induced by intraperitoneal administration of streptozotocin. Other manifestations of diabetic nephropathy were also attenuated in FVL mice, including extracellular matrix accumulation, the number of apoptotic cells in glomeruli, and podocyte loss and dysfunction. These findings were corroborated by the observation that type 1 and type 2 diabetes patients heterozygous for the FVL mutation showed reduced albuminuria compared with diabetes patients without FVL who were similar with regard to other risk factors for diabetic nephropathy such as glucose control.

Comment on Wang et al, page 5231

Thrombin and diabetic nephropathy

Tom van der Poll  CENTER OF INFECTION AND IMMUNITY AMSTERDAM

The coagulation system is regulated by several anticoagulant mechanisms.1 The Protein C system provides important control of coagulation via the capacity of activated protein C (APC) to proteolytically inactivate the coagulation cofactors Va and VIIIa.

Protein C is converted into APC by thrombin bound to thrombomodulin, a receptor present on the vascular endothelium, in a process strongly augmented by the presence of the endothelial protein C receptor (EPCR).

The factor V Leiden (FVL) mutation is a missense mutation in FV gene replacing arginine at position 506 with glutamine, which results in resistance of activated FV to inactivation by APC and causes increased thrombin formation and, thereby, an elevated risk of (mainly venous) thrombotic events.2 The high prevalence of this mutation (4%-6% in Caucasians) despite its prothrombotic effects has prompted speculation that the mutation might be subject to positive selection pressure.3 In the current issue of Blood, Wang et al report that one such evolutionary advantage of the FVL mutation may be protection against diabetic nephropathy (see figure).4

Diabetic nephropathy is a leading cause of end-stage renal failure in the developed world, with albuminuria, a key abnormality, caused by loss and dysfunction of podocytes.5 Wang and colleagues established that the FVL mutation reduces the extent of diabetic nephropathy using an approach that elegantly combines mouse and human studies.6 Relative to normal wild-type mice, heterozygous and homozygous FVL mice displayed reduced albuminuria after 26 weeks of persistent hyperglycemia induced by intraperitoneal administration of streptozotocin. Other manifestations of diabetic nephropathy were also attenuated in FVL mice, including extracellular matrix accumulation, the number of apoptotic cells in glomeruli, and podocyte loss and dysfunction. These findings were corroborated by the observation that type 1 and type 2 diabetes patients heterozygous for the FVL mutation showed reduced albuminuria compared with diabetes patients without FVL who were similar with regard to other risk factors for diabetic nephropathy such as glucose control.
The yin and yang of Activin A
Silvano Sozzani and Tiziana Musso